On June 9, 2025, Avidity Biosciences announced it will host an event discussing FDA feedback for accelerated approval of delpacibart braxlosiran for FSHD, and initiated a Phase 3 study to support full approval. Positive topline data from earlier trials showed improvements in muscle function and safety, while the company plans to submit a biologics license application in late 2026.